TYK Medicines (HKSE:02410) ROC (Joel Greenblatt) %: -176.44% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02410 TYK Medicines Inc HKSE:02410
6 GF Score
Price HK$6.33
! 3 Warning Signs
View Full Analysis

What is TYK Medicines ROC (Joel Greenblatt) %?

TYK Medicines HKSE:02410 -5.03% 6 ROC (Joel Greenblatt) % is -176.44% as of Dec. 2025. GuruFocus rates HKSE:02410 with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 1,325 Biotechnology companies, TYK Medicines ranks better than 61.96% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. TYK Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -176.44%.

The historical rank and industry rank for TYK Medicines's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:02410' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -229.77   Med: -209.74   Max: -91.8
Current: -91.8

During the past 4 years, TYK Medicines's highest ROC (Joel Greenblatt) % was -91.80%. The lowest was -229.77%. And the median was -209.74%.

HKSE:02410's ROC (Joel Greenblatt) % is ranked better than
61.96% of 1325 companies
in the Biotechnology industry
Industry Median: -301.94 vs HKSE:02410: -91.80

TYK Medicines's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


TYK Medicines  (HKSE:02410) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


TYK Medicines ROC (Joel Greenblatt) % Related Terms


TYK Medicines ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for TYK Medicines's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TYK Medicines ROC (Joel Greenblatt) % Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
-229.77 -224.84 -194.63 -150.67

TYK Medicines Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial -194.48 -150.64 -108.56 -176.44 -17.45

HKSE:02410 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, TYK Medicines's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TYK Medicines ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where TYK Medicines's ROC (Joel Greenblatt) % falls into.


HKSE:02410
6GF Score
TYK Medicines Inc HKSE:02410
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TYK Medicines ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 27.326) - (56.611 + 0 + 55.825)
=-85.11

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 99.463) - (114.546 + 0 + 60.893)
=-75.976

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of TYK Medicines for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-407.29/( ( (232.321 + max(-85.11, 0)) + (229.344 + max(-75.976, 0)) )/ 2 )
=-407.29/( ( 232.321 + 229.344 )/ 2 )
=-407.29/230.8325
=-176.44 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -176.44% mean?
TYK Medicines (HKSE:02410) has a ROC (Joel Greenblatt) % of -176.44% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on TYK Medicines and its competitors. According to the industry distribution chart, TYK Medicines ranks #504 out of 1325 companies in the Biotechnology industry, placing it in the top 38%.
Is TYK Medicines' ROC (Joel Greenblatt) % too high?
TYK Medicines' current ROC (Joel Greenblatt) % is -176.44%. Based on the distribution chart, TYK Medicines ranks #504 out of 1325 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TYK Medicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TYK Medicines ranks #504 out of 1325 companies for ROC (Joel Greenblatt) %. This puts TYK Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on TYK Medicines and its competitors. TYK Medicines's current ROC (Joel Greenblatt) % is -176.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current ROC (Joel Greenblatt) % of -176.44%. The current ROC (Joel Greenblatt) % is -176.44%. TYK Medicines' overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current ROC (Joel Greenblatt) % is -176.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TYK Medicines Business Description

Address No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
6GF Score

Get the complete analysis for HKSE:02410

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.33
Price